Litcius/Paper detail

LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial

Binghe Xu, Qilong Zhang, Ping Zhang, Zhong Sheng Tong, Tao Sun, W. Li, Quchang Ouyang, Xin Hu, Y. Cheng, Min Yan, Yuee Teng, Yacheng Pan, Xiaoyu Yan, Yue Wang, Wenqiang Xie, Xiaohua Zeng, Shuping Jiang, Nayima Bayaxi, Xinyu Zhu

2022Annals of Oncology15 citationsDOIOpen Access PDF

Topics & Concepts

AnastrozoleMedicineLetrozoleFulvestrantInternal medicineClinical endpointBreast cancerPlaceboNeutropeniaMetastatic breast cancerOncologyInterim analysisPhases of clinical researchProgression-free survivalRandomized controlled trialCancerTamoxifenClinical trialChemotherapyAlternative medicinePathologyAdvanced Breast Cancer TherapiesCancer Treatment and PharmacologyHER2/EGFR in Cancer Research
LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial | Litcius